COMPANY

Klus Pharma

HQ: Princeton, NJ source · kluspharma.com ↗ · Mid-Atlantic

Our proprietary discovery and development platform for therapeutic antibodies, which provides full coverage on all key steps in preclinical development. From company website Source · Oct 13, 2026

Keywords: preclinical antibodies Non-Small Cell Lung Cancer Cervical Cancer Epithelial Ovarian Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Urothelial Carcinoma Small-Cell Lung Cancer Endometrial Carcinoma Head and Neck Squamous Cell Carcinoma Breast Cancer HER2-positive Breast Cancer HER2 Gene Mutation HER-2 Gene Amplification HER2 Positive Gastric Cancer Salivary Gland Cancer Salivary Gland Tumor Salivary Gland Carcinoma Salivary Gland Neoplasms Lung Cancer Colo-rectal Cancer Rare Diseases Recurrent Gastric Cancer Recurrent Colon Cancer Recurrent Breast Cancer Head and Neck Cancer Head and Neck Carcinoma Bladder Cancer Liver Cancer Bile Duct Cancer Urologic Cancer Pancreatic Cancer Prostate Cancer Recurrent Prostate Cancer Rectal Cancer Recurrent Ovarian Carcinoma Recurrent Renal Cell Cancer Rectal Cancer Stage II Rectal Cancer Stage I Rectal Cancer Stage III Skin Cancer

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

Apr 19, 2023 Trial start Phase 2: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) source ↗
Jan 17, 2023 Trial start Phase 2: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors source ↗
Feb 28, 2020 Trial start I: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) source ↗
Jul 16, 2018 Trial start Phase 1/Phase 2: Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene source ↗

Upcoming milestones

Nov 30, 2027 (ESTIMATED) · Phase 2 · SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors · NCT05642780

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT04152499	Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)	I	Active, not recruiting	Feb 28, 2020	Nov 30, 2025 (actual)
NCT05816252	A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)	Phase 2	Active, not recruiting	Apr 19, 2023	Jun 30, 2026 (estimated)
NCT05642780	SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors	Phase 2	Active, not recruiting	Jan 17, 2023	Nov 30, 2027 (estimated)
NCT03602079	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	Phase 1/Phase 2	Completed	Jul 16, 2018	Jan 12, 2022 (actual)

Connect

Contact page